Abeona Therapeutics Inc. $ABEO Stock Holdings Cut by Propel Bio Management LLC

Posted by Francis Steltz on Jun 7th, 2026

Propel Bio Management LLC decreased its holdings in shares of Abeona Therapeutics Inc. (NASDAQ:ABEO – Free Report) by 14.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 830,780 shares of the biopharmaceutical company’s stock after selling 143,242 shares during the quarter. Abeona Therapeutics comprises about 3.7% of Propel Bio Management LLC’s investment portfolio, making the stock its 10th largest position. Propel Bio Management LLC’s holdings in Abeona Therapeutics were worth $4,378,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of ABEO. Goldman Sachs Group Inc. increased its position in Abeona Therapeutics by 49.6% during the first quarter. Goldman Sachs Group Inc. now owns 200,450 shares of the biopharmaceutical company’s stock valued at $954,000 after acquiring an additional 66,422 shares during the last quarter. Geode Capital Management LLC grew its holdings in Abeona Therapeutics by 129.1% during the 2nd quarter. Geode Capital Management LLC now owns 1,105,862 shares of the biopharmaceutical company’s stock valued at $6,282,000 after purchasing an additional 623,243 shares during the last quarter. Creative Planning grew its holdings in Abeona Therapeutics by 43.0% during the 2nd quarter. Creative Planning now owns 14,310 shares of the biopharmaceutical company’s stock valued at $81,000 after purchasing an additional 4,305 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Abeona Therapeutics by 255.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 831,132 shares of the biopharmaceutical company’s stock valued at $4,721,000 after purchasing an additional 597,373 shares during the last quarter. Finally, Legal & General Group Plc bought a new position in Abeona Therapeutics during the 2nd quarter valued at about $27,000. Institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Stock Down 6.2%

Shares of ABEO opened at $5.46 on Friday. The firm has a market capitalization of $311.17 million, a P/E ratio of 5.63 and a beta of 1.35. Abeona Therapeutics Inc. has a 12-month low of $4.00 and a 12-month high of $7.54. The company has a current ratio of 5.89, a quick ratio of 5.70 and a debt-to-equity ratio of 0.03. The firm has a fifty day moving average price of $5.33 and a 200-day moving average price of $5.14.

Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) last issued its earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.03. The company had revenue of $8.72 million for the quarter, compared to analysts’ expectations of $4.57 million. Equities research analysts expect that Abeona Therapeutics Inc. will post -0.79 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Oppenheimer reiterated an “outperform” rating on shares of Abeona Therapeutics in a report on Monday, March 9th. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Abeona Therapeutics in a report on Thursday, May 28th. Wall Street Zen upgraded shares of Abeona Therapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, June 1st. Finally, Stifel Nicolaus set a $17.00 target price on shares of Abeona Therapeutics in a research note on Tuesday, March 17th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $19.00.

Read Our Latest Analysis on ABEO

Insider Activity at Abeona Therapeutics

In related news, Director Eric Crombez sold 26,143 shares of Abeona Therapeutics stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $5.53, for a total value of $144,570.79. Following the completion of the sale, the director directly owned 37,313 shares in the company, valued at $206,340.89. The trade was a 41.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Madhav Vasanthavada sold 5,548 shares of Abeona Therapeutics stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $5.96, for a total value of $33,066.08. Following the completion of the sale, the insider owned 313,071 shares of the company’s stock, valued at $1,865,903.16. The trade was a 1.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 38,191 shares of company stock worth $213,127 over the last three months. 7.10% of the stock is owned by corporate insiders.

Abeona Therapeutics Profile

(Free Report)

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.